Sponsors (2)
The bill increases transparency and modernizes evidence pathways (including promoting non-animal methods) to speed and clarify access to OTC topical drugs and sunscreens, but it raises trade-offs between faster, broader approval routes and potential risks from lower-evidence standards, transitional regulatory uncertainty, and short-term costs to industry.
Consumers (general public, patients, uninsured individuals) will get clearer, more transparent regulatory standards and public reporting for over-the-counter topical drugs and sunscreens, improving product safety, confidence, and availability and supporting skin cancer prevention (recognition of broad-spectrum SPF 15+).
Manufacturers, researchers, and small businesses will face more streamlined and predictable review pathways through harmonized testing standards (including alignment with 21 U.S.C. 355h) and a one-year draft-guidance deadline, reducing regulatory uncertainty and helping bring OTC topical products to market faster.
The bill promotes and accelerates adoption of validated non-animal (nonclinical) testing methods for topical products by encouraging alternatives and by publicly tracking FDA progress, reducing reliance on animal studies and supporting ethical and scientific modernization.
Consumers (patients and the general public) could face increased risk of unsafe or ineffective OTC topical products if acceptance of real-world evidence or broader alternative tests allows lower-standard evidence into approvals, and statutory evidentiary requirements could limit FDA flexibility to exclude novel but safe ingredients.
Expanding acceptable evidence types, specifying evidentiary standards in statute, and adding detailed public reporting may create regulatory transition costs and uncertainty, slow FDA rulemaking or reviews in some cases, and divert agency resources from other work.
Manufacturers and research groups may incur short-term increased costs to invest in new nonclinical testing infrastructure and face concerns about disclosure of proprietary information from expanded public reporting of sunscreen active reviews.
Based on analysis of 4 sections of legislative text.
Requires FDA to accept real‑world evidence and non‑animal testing alternatives for reviewing nonprescription topical drugs (including sunscreens), issue guidance in 1 year, and report to Congress annually.
Requires the FDA to accept real‑world evidence along with clinical trials when evaluating whether nonprescription topical drug active ingredients (including sunscreen actives) are generally recognized as safe and effective, while keeping the FDA’s authority to weigh benefits and risks. Directs FDA to consider specified nonclinical (non‑animal) tests for topical drugs, issue a draft guidance on non‑animal test alternatives within one year, and report to Congress about implementation and progress on testing alternatives starting 18 months after enactment and annually for five years. Also requires any final administrative order on nonprescription sunscreen active ingredients to account for past U.S. marketing safety data and the role of broad‑spectrum sunscreens with SPF 15+ in skin cancer prevention, and to follow the evidence and testing rules established in this Act.
Introduced July 29, 2025 by Margaret Wood Hassan · Last progress July 29, 2025